Janus Henderson Hrzn Biotec A2 HEUR |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | - | - | - | 18.7 | 1.5 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 17/05/2024 | EUR 19.02 | |
Day Change | 0.42% | |
Morningstar Category™ | Other Equity | |
ISIN | LU2441282972 | |
Fund Size (Mil) 30/04/2024 | USD 257.42 | |
Share Class Size (Mil) 17/05/2024 | EUR 0.70 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 14/02/2024 | 1.89% |
Investment Objective: Janus Henderson Hrzn Biotec A2 HEUR |
The Sub-Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its net assets in equities or equity-related instruments of biotechnology and biotechnology-related companies worldwide. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Daniel Lyons 10/12/2018 | ||
Agustin Mohedas 31/01/2023 | ||
Click here to see others | ||
Inception Date 25/02/2022 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Janus Henderson Hrzn Biotec A2 HEUR | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 7.91 |
Amgen Inc | Healthcare | 7.83 |
Avadel Pharmaceuticals PLC ADR | Healthcare | 3.65 |
argenx SE ADR | Healthcare | 3.45 |
Sarepta Therapeutics Inc | Healthcare | 3.26 |
Increase Decrease New since last portfolio | ||
Janus Henderson Hrzn Biotec A2 HEUR |